We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
U.S. Patent Office Issues Vermillion Patent for Biomarkers Detecting Ovarian Cancer
News

U.S. Patent Office Issues Vermillion Patent for Biomarkers Detecting Ovarian Cancer

U.S. Patent Office Issues Vermillion Patent for Biomarkers Detecting Ovarian Cancer
News

U.S. Patent Office Issues Vermillion Patent for Biomarkers Detecting Ovarian Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "U.S. Patent Office Issues Vermillion Patent for Biomarkers Detecting Ovarian Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vermillion, Inc. has announced that the U.S. Patent Office (USPTO) has issued patent number 7,605,003 titled "Use of biomarkers for detecting ovarian cancer" to the Company for the discovery of biomarkers for ovarian cancer.

The patent covers biomarker combinations for both the diagnosis and management of ovarian cancer and covers measurement of the markers by a variety of methods, including mass spectrometry and immunoassay approaches.

"Vermillion has been creating a comprehensive patent portfolio to protect our ovarian cancer testing franchise. The issuance of this patent supports our overall intellectual property strategy and we continue to pursue additional patent applications in support of our diagnostic programs," said Gail S. Page, Vermillion Executive Chairperson.
Advertisement